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Radiofrequency Ablation Treatment for
Renal Cell Carcinoma: Early Clinical
Experience
Objective: To evaluate the early clinical experience associated with radiofre-
quency (RF) ablation in patients with renal cell carcinoma (RCC).
Materials and Methods: The RF ablation treatment was performed on 17
tumors from 16 patients (mean age, 60.5 years; range, 43 73 years) with RCC.
The treatment indications were localized, solid renal mass, comorbidities, high
operation risk, and refusal to perform surgery. All tumors were treated by a percu-
taneous CT (n = 10), followed by an US-guided (n = 2), laparoscopy-assisted US
(n = 2), and an open (n = 2) RF ablation. Furthermore, patients underwent a fol-
low-up CT at one day, one week, one month, three and six months, and then
every six months from the onset of treatment. We evaluated the technical suc-
cess, technical effectiveness, ablation zone, benign periablation enhancement,
irregular peripheral enhancement, and complications.
Results: All 17 exophytic tumors (mean size, 2.2 cm; range, 1.1 5.0 cm) were
completely ablated. Technical success and effectiveness was achieved in all
cases and the mean follow-up period was 23.8 months (range, 17 33 months). A
local recurrence was not detected in any of the cases; however, five patients
developed complications as a result of treatment, including hematuria (n = 2),
mild thermal injury of the psoas muscle (n = 1), mild hydronephrosis (n = 1), and
fistula formation (n = 1).
Conclusion: The RF ablation is an alternative treatment for exophytic RCCs
and represents a promising treatment for some patients with small RCCs.
enal cell carcinoma (RCC) is the third most common genitourinary
tumor, accounting for 2% of all adult cancers (1). The incidence of RCC
continues to increase with over 30,000 new cases recorded in the United
States for the year 2000 (1). This increase is associated with the advent of modern
imaging techniques such as ultrasonography and CT, which can detect very early
clinical stage small and localized renal tumors. Previous studies have found that
kidney tumors measuring less than 3 cm in diameter are generally not associated with
metastasis (2). At the same time, recent advances have led to the use of nephron-
sparing surgery techniques, such as a partial nephrectomy or laparoscopic nephrec-
tomy in selected patients with small renal tumors (3, 4). Some patients, however, are
not ideal candidates for renal tumor resections because of comorbidities, limited renal
functional reserve, or other complicating factors (5). Therefore, for patients that are
unsuitable for surgical interventions or with small tumors, minimally invasive
therapies capable of destroying tumors without damaging renal functions would be
particularly useful (6).
Radiofrequency (RF) ablation is a thermal ablation method that uses high frequency
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Renergy to induce cell death. The conduction of the RF
causes molecular friction and heat. In turn, this heat energy
induces tissue necrosis as a result of denaturation and
coagulation. RF ablation has been utilized in early clinical
trials for the treatment of hepatocellular carcinoma,
hepatic and cerebral metastasis, as well as benign bone
tumors such as osteoid osteomas (7 10). In 1998, a case
report was published describing the use of a percutaneous
RF ablation under ultrasound guidance as the treatment of
choice for RCC in human patients (11). It is anticipated
that RF ablation will provide a minimally invasive
technique for treating small renal tumors. The purpose of
this study is to evaluate our early experience with patients
who underwent RF ablations for treatable localized renal
tumors, retrospectively.
MATERIALS AND METHODS
Patients Selection
Between August 2004 and December 2005, 17 RF
ablations were performed on 16 patients (4 females and 12
males) with renal tumors. The mean patient age was 60.5
years (range, 43 73 years) and the diagnosis of RCCs was
based on the fine needle biopsy results in eight renal
tumors. The nine remaining renal tumors were treated on
the basis of CT results that were consistent with RCC.
Indications for RF ablations included coexistent morbidities
(n = 5), high surgical or anesthetic risks (n = 6), refusal to
undergo surgery (n = 3), and the presence of bilateral
RCCs (n = 2). The location of the renal tumors were classi-
fied as exophytic, central, or mixed based on their location
(12, 13). Prothrombin time, partial thromboplastin time,
complete blood count, and serum creatinine level were
assessed before and after RF ablation in all cases. Informed
consent was obtained for the procedure in all cases. The
Institutional Review Board was not required for retrospec-
tive studies at Dong-A University. The patient characteris-
tics are summarized in Table 1.
Radiofrequency (RF) Ablation
A percutaneous CT (n = 10) or US-guided (n = 2) RF
ablation was performed in 12 of 16 patients. An RF
ablation was performed under laparoscopy-assisted US
guidance (n = 2) and the open approach (n = 2) with the
remaining patients. A percutaneous RF ablation was
performed under intravenous sedation with 2 4 mg of
midazolam hydrochloride (Roche, Fontenaysous-Bois,
France) and 100-300  g of fentanyl citrate (Hana Pharm.
Co., Hwasung, Korea). Local analgesia with 2% lidocaine
(Huons, Hwaseong, Korea) was administered in combina-
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Table 1. Summary of Patient Characteristics
Patients Age/Sex Indication for RF Ablation
No. of  Tumor Size  Tumor  Diagnosis 
Lesions (cm) Location Method
Approach
01 67/M Bilateral renal tumor, 2 1.6 Exophytic Biopsy
RSG for AGC 2.0 Exophytic Biopsy Percutaneous CT
02 45/F Jehovah`s witnesses 1 2.4 Exophytic Biopsy Percutaneous US
03 43/F Acute cholecystitis, 1 2.5 Exophytic CT Laparoscopic US
VPC, emphysema 
04 64/M Bilateral renal tumor, 1 2.8 Exophytic Biopsy Percutaneous US
hypertension
05 60/F DM 1 3.5 Exophytic CT Percutaneous CT
06 62/M Thyrotoxicosis, 1 1.8 Exophytic CT Laparoscopic US
ischemic heart disease
07 73/M DM, gout 1 1.6 Exophytic Biopsy Open
08 66/M Esophageal cancer 1 1.9 Exophytic Biopsy Open
09 70/M Pulmonary tuberculosis, 1 5.0 Exophytic CT Percutaneous CT
bronchiectasis, DM
10 66/M Colectomy for sigmoid cancer 1 2.7 Exophytic CT Percutaneous CT
11 56/F Hypertension 1 2.1 Exophytic CT Percutaneous CT
12 49/M DM 1 3.9 Exophytic Biopsy Percutaneous CT
13 71/M Refusal of surgery 1 3.0 Exophytic Biopsy Percutaneous CT
14 67/M Aortic dissection 1 2.4 Exophytic CT Percutaneous CT
15 58/M Prostate carcinoma 1 2.2 Exophytic CT Percutaneous CT
16 51/M Refusal of surgery 1 3.6 Exophytic CT Percutaneous CT
Note. RSG = radical subtotal gastrectomy, AGC = advanced gastric cancer, VPC = ventricular premature contraction, DM = diabetes mellitus, 
No. = number tion with intravenous analgesia. The patients were placed
in a prone or modified lateral position, according to the
tumor location. An open or laparoscopic approach was
inducted by general anesthesia using 100 300 mg of
propofol (Dongkook Pharm Co., Jincheon, Korea) in four
patients. All patients required hospital admission after the
RF ablation for close observation.
An RF ablation was performed with a 200 W generator
(Radionics, Burlington, MA) using single (with one 2.0 3.0
cm tip) internally cooled electrodes (Radionics, Burlington,
MA) with impedance-controlled pulsed current. The length
of the exposed tip was chosen by the operator based on
tumor size and location. The active treatment time was 12
minutes, as per the manufacturer’s recommendations.
Based on the size and location of the lesion, overlapping
ablations were performed by repositioning the electrode to
ablate the entire tumor. A session was defined as one visit
at the radiology department, in which one or more RF
applications were performed. 
Imaging and Follow-up 
All patients underwent a contrast-enhanced CT before
and after an RF ablation. A follow-up CT was performed
at one day, one week, one month, three and six months,
and then every six months thereafter. In addition, a follow-
up CT was performed at one day and one week to assess
the technical success and immediate or periprocedural
complication. A one month follow-up CT was performed
to determine whether additional ablation treatment was
required. In addition, a follow-up CT was performed after
three and six months, and then every six months to detect
any new areas of enhancement or an increase in lesion size
in ablated tumor region. The treated tumors were assessed
for technical success, technical effectiveness, ablation zone,
benign periablation enhancement, irregular peripheral
enhancement, and complications upon a follow-up CT.
Tumors that were treated to the full extent according to
the protocol, which was assessed at the time of the
procedure, were considered to be technically successful.
Technical effectiveness refers to a prospectively defined
point in time at which “complete ablation” of the
macroscopic tumor, confirmed by follow-up imaging, was
achieved. The technical effectiveness rate was defined as
the percentage of tumors that were successfully eradicated
following the initial procedure or additional sessions within
a one month follow-up period.
The ablation zone was defined by measuring the size
change of the minimal contrast enhancement (i.e. < 20 HU
for CT) observed by radiological imaging soon after the
ablation. The benign periablation enhancement was
Park et al.
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Table 2. Summary of Radiofrequency Ablation Results
Number Number  Follow-up  Duration  of Presence  of
Patients of  of  Duration Benign Periablation  Irregular Peripheral  Complications
Sessions Treatments (months) Enhancement Enhancement
1 1 1 33 1 week None None
11 3 3
2 1 1 32 1 week None None
3 1 1 31 1 week None None
4 1 1 27 1 week None None
5 1 2 27 1 month None Gross hematuria
6 1 1 26 None None None
7 1 1 25 3 months None Mild hydronephrosis
8 1 1 24 None None None
9 3 1st visit: 6 20 None Yes Gross hematuria
2nd visit: 5
3rd visit: 4
10 1 1 20 None None None
11 1 1 24 None None Fistula formation
12 2 1st visit: 4 19 None Yes Mild thermal injury
2nd visit: 1 on psoas muscle
13 2 1st visit: 1 17 1 week Yes None
2nd visit: 3
14 2 1st visit: 2 17 None Yes None
2nd visit: 2
15 1 2 17 None None None
16 1 2 17 None None Nonedefined as a thin, concentric, and uniform rim peripheral
enhancement with smooth inner margins on a contrast-
enhanced CT. On the other hand, an irregular peripheral
enhancement was defined as a scattered, nodular, or
eccentric peripheral enhancement on a follow-up CT. 
We analyzed the rate of complication based on the
following time categories following the ablation: 6 24
hours, periprocedural complications (within 30), and
delayed complications (greater than 30 days).
RESULTS
The treatment data for each patient are summarized in
Table 2. All the 17 renal tumors observed in the 16
patients were subjected to an RF ablation treatment. The
mean tumor size was 2.2 cm (range, 1.6 5.0 cm), and all
tumors were exophytic. The mean CT follow-up period
was 23.8 months (range, 17 33 months). Over the
radiologic follow-up period, a total of 13 tumors in 12
patients were successfully treated in one ablation session
(Fig. 1), and four tumors from four patients required more
than one session based upon follow-up CT scan results.
One tumor required 3 sessions, as a result of persistent
enhancement within the tumor. Also, seven tumors from
seven patients required electrode repositions since the
tumor size was too large. Technical success and technical
effectiveness rates were achieved in all cases (100%) and
the mean total procedure time was 97.8 minutes (range,
32 260 minutes). However, except for the open
approach, the mean procedure time was 83.6 minutes.
The postablation serum creatinine levels were analyzed,
and revealed that one patient (patient 6) showed an
increase in creatinine levels (from 1.2 to 1.5 mg/dl);
however, levels returned to a normal range after seven
RF Ablation for Renal Cell Carcinoma
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Fig. 1. Well ablated, small exophytic
renal cell carainoma in 56-year-old
woman who underwent RF ablation.
A. Contrast-enhanced CT scan before
RF ablation demonstrates solid enhanc-
ing exophytic renal tumor located at
lower polar region of left kidney (arrow).
B. RF ablation of tumor was performed
under CT guidance. Unenhanced CT
scan during treatment demonstrates
electrode within renal tumor (arrow).
C. One-month follow-up contrast-
enhanced CT scan demonstrates no
periablation enhancement or residual
contrast enhancement within tumor bed
(arrow), indicating technical success.
D. Two-year follow-up contrast-
enhanced CT scan demonstrates no
areas of abnormal contrast enhance-
ment within tumor and shows further
decrease in size of renal tumor (arrow).days.
Upon a follow-up CT, all the tumors revealed a variable
degree of size reduction (mean diameter, 0.6 cm; range,
0.2 1.7 cm) compared to the pretreatment CT. Irregular
peripheral enhancement, indicating incomplete ablation,
was noted in four tumors from the one day follow-up CT.
As a result, additional procedure sessions were performed.
A benign periablation enhancement was observed in eight
tumors from seven patients, which disappeared within
three months in all tumors (Fig. 2). No tumors were
detected in our patients developed metastases during the
follow-up period.
Five patients (31%) experienced postablation complica-
tions, with immediate complications noted in three
patients. Two patients developed gross hematuria after a
single ablation, which was resolved within four days. In
one patient, a mild thermal injury of the psoas muscle was
noted in patients with tumors abutting these areas after the
second session. Periprocedural or delayed complications
were reported in two patients. In addition, a mild case of
hydronephrosis was noted in one patient with a 1.6 cm
sized tumor located in the anterior lower pole of the right
kidney and has been continued on a follow-up CT (Fig. 3).
Moreover, another patient had a small amount of contrast
leakage noted from a 12 month follow-up CT, which had a
suspected fistula formation. These two patient’s creatinine
levels were below normal range and no symptoms were
noted in the follow-up CT period. Furthermore, no patients
Park et al.
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Fig. 2. Small exophytic renal cell
carcinoma in 45-year-old woman.
A. Contrast-enhanced CT before RF
ablation demonstrates enhancing
exophytic renal tumor located at lower
polar region of right kidney (arrow).
B. One-day follow-up contrast-enhanced
CT scan demonstrates peripheral,
curvilinear enhancement (arrow) in
ablated tumor, indicating possible
reactive hyperemia or remnant tumor.
C. One-month follow-up contrast-
enhanced CT scan demonstrates no
previous peripheral enhancement
(arrow) and any residual contrast
enhancement within tumor, suggesting
benign periablation enhancement.
D. Two-year follow-up contrast-
enhanced CT scan demonstrates no
evidence of enhancement within
ablation zone (arrow). required a blood transfusion, intensive care or additional
therapy.
DISCUSSION
Management options for RCCs continue to evolve, with
the most recent developments in the areas of nephron-
sparing and laparoscopic procedures (3, 4). The trend
toward less invasive RCC treatments is at least partly due
to the increasing number of RCCs diagnosed today. A
percutaneous RF ablation of malignant tumors has been
developed as a feasible option for patients with primary
and metastatic hepatic lesions that are not good candidates
for traditional surgery (7, 8). This approach may have a
role in the management of renal tumors. One report in the
long-term data following an RF ablation concluded that the
RF ablation technique was the most successful treatment of
small exophytic renal tumors (12).
Tumor size is an important predictor of successful
treatment in RF ablation of renal tumors. Despite advances
in electrode design, the successful ablation of tumors,
greater than 4 cm in diameter, has been a challenge (14).
Therefore, smaller renal tumors are ideal candidates for an
RF ablation. On the other hand, the larger tumors require
multiple overlapping ablations and, in some cases, return
visits for additional ablation sessions (12, 13).
The location of the tumor within the kidney may also
play an important role in the efficacy of the RF ablation
treatment for renal masses, and may influence the success
of an ablation. A central tumor ablation fails more
frequently because of a heat sink effect, in which a regional
vascular flow reduces the extent of the thermally induced
coagulation (15). By contrast, exophytic lesions are
surrounded by perirenal fat, which serves as a heat insula-
tor and allows the achievement of higher temperatures
during RF ablation. This phenomenon was first described
in liver tumors and referred to as the “oven effect” where
hepatic tumors surrounded by a fibrotic capsule and
surrounding cirrhotic liver tissue are more easily treated
(16). As a result of this phenomenon, exophytic renal
tumors have an increased likelihood of successful ablation.
Therefore, size and location are good predictors of success,
with small exophytic renal tumors being the most suitable
candidates for RF ablation (12, 13, 17 19). These consid-
erations led us to perform an RF ablation for exophytic or
peripherally located tumors only. All 17 tumors up to 5 cm
in diameter (small or intermediate tumors) were success-
fully treated after the completion of the procedures. 
We usually performed an RF ablation using a percuta-
neous CT guidance. At the beginning of the RF ablation, a
percutaneous US-guided approach was performed in two
patients. However, we preferred the CT guidance because
the electrode was more reliably placed, and the production
of gas at the ablation site did not obscure the lesion for
additional treatments. Consequently, an overlapping
ablation was easily performed by repositioning the
electrode.
For patients with difficult access points (patients with
multiple lesions in a solitary kidney, an intervening lung
parenchyma, bowel, or thin patients with an anterior
lesion) or comorbidities, a laparoscopy-assisted US
guidance or open intraoperative RF ablations should be
considered as a treatment option. Among all of the study
cases, the open intraoperative RF ablation was carried out
in two patients, in which, one operation was performed as
a result of esophageal cancer with RF ablation. In addition,
two patients were treated with a laparoscopy-assisted US
guided RF ablation to isolate the targeted tumors away
RF Ablation for Renal Cell Carcinoma
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Fig. 3. Development of mild
hydronephrosis in 73-year-old male
patient who underwent RF ablation for
renal cell carcinoma.
A. Contrast-enhanced CT scan before
RF ablation reveals 1.6 cm solid
enhancing exophytic renal tumor located
at lower polar region of right kidney
(arrow).
B. Three-month follow-up contrast-
enhanced CT scan shows no remnant
contrast enhancement (arrow) in tumor
but reveals mild hydronephrosis
(arrowheads) in right kidney. Patient did
not require interventional procedure for
hydronephrosis.
A Bfrom adjacent the normal structure, such as the colon or
psoas muscle.
We evaluated follow-up images using the criteria
reported by Goldberg et al. (6) and assessed the treated
RCCs for lesion size as well as benign periablation
enhancement and irregular peripheral enhancement. A
benign periablation enhancement typically suggests a
benign physiologic response to a thermal injury (initially:
reactive hyperemia, subsequently: fibrosis and giant cell
reaction). This transient finding, measuring up to 1 2 mm
can be observed immediately after ablation, and can last
for up to 3 months after the ablation. An irregular periph-
eral enhancement represents a residual tumor that may
occur at the treatment margin. This lesion grows in a
scattered, nodular, or eccentric pattern, which indicates an
incomplete local treatment (i.e. residual unablated tumor)
(6). In this study, a benign periablation enhancement was
identified in eight tumors from seven patients and the
mean duration of its existence was 20.2 days (range, 1
week 3 months). An irregular peripheral enhancement
was noted in four tumors, followed by additional
procedure sessions.
An RF ablation can cause various complications. Major
complications, include hemorrhaging requiring a transfu-
sion, ureteral strictures, tumor seeding in the electrode
track, and urine leakage. Minor complications in the RF
ablation include self-limited paresthesias and transient
hematuria (12, 17). In our study, five complications were
encountered; however, all patients were successfully
treated without long-term adverse effects. The patient
diagnosed with a mild case of hydronephrosis, after having
undergone an RF ablation, was discovered to have a tumor
located just adjacent to the renal pelvis and was managed
by supportive care without any intensive interventions.
However, the patient required a longer hospital admission
than the other patients enrolled in the study. One patient
was temporarily diagnosed with a moderate elevation in
serum creatinine levels following an RF ablation; however,
the patient’s creatinine levels returned to within a normal
range after seven days. It is presumed that acute renal
failure occurred as a result of the renal hypoperfusion
during the laparoscopic procedure. The results of this study
suggest that image-guided RF ablation of small localized
renal tumors is a safe procedure with an extremely low
major complication rate.
Despite the findings, this study had several limitations,
including patient sample size and the relatively short
follow-up period (23.8 months). Therefore, a long-term
radiographic and clinical follow-up would be required to
assess the oncologic outcome of RF ablations. In addition,
the histopathologic diagnosis was not confirmed in nine
renal tumors. However, over 90% of the solid renal
masses are RCC. Lastly, imaging follow-ups were only
performed with contrast-enhanced CT scans to determine
the extent of an “unablated residual tumor”.
In conclusion, the RF ablation is a minimally invasive
procedure that appears to be a safe and effective treatment
for small localized exophytic renal tumors. Those lesions
not amenable to a percutaneous RF ablation could be
treated with laparoscopy-assisted US-guided or open
intraoperative RF ablation. Although, the mean follow-up
period in this study was relatively short, our early experi-
ence with RF ablation demonstrates that it is a safe and
effective treatment for small exophytic renal tumors in a
selected group of patients.
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